nach oben

International Journal of Clinical Oncology

Erschienen in:

15.07.2016 | Original Article

Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study

verfasst von: Hiroki Ishihara, Tsunenori Kondo, Kenji Omae, Toshio Takagi, Junpei Iizuka, Hirohito Kobayashi, Yasunobu Hashimoto, Kazunari Tanabe

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

We aimed to evaluate the effect of sarcopenia, a condition of low muscle mass, on the survival among patients who were undergoing radical nephroureterectomy (RNU) for urothelial carcinoma of the upper urinary tract (UCUT).

Methods

We retrospectively reviewed consecutive patients with UCUT (cT[any]N0M0) who underwent RNU between 2003 and 2013 at our department and its affiliated institutions. Preoperative computed tomography images were used to calculate each patient’s skeletal muscle index, an indicator of whole-body muscle mass. Sarcopenia was defined according to the sex-specific consensus definitions, based on the patient’s skeletal muscle and body mass indexes. We analyzed the relapse-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) after RNU to identify factors that predicted patient survival.

Results

A total of 137 patients were included, and 90 patients (65.7 %) were diagnosed with sarcopenia. Compared to the non-sarcopenic patients, the sarcopenic patients had a significant inferior 5-year RFS (48.8 vs. 79.6 %, p = 0.0002), CSS (57.1 vs. 92.6 %, p < 0.0001), and OS (48.2 vs. 90.6 %, p < 0.0001). Multivariate analyses revealed that sarcopenia was an independent predictor of shorter RFS, CSS, and OS (all, p < 0.0001).

Conclusions

Sarcopenia was an independent predictor of survival among patients with UCUT who were undergoing RNU.

Martin L, Birdsell L, Macdonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol Off J Am Soc Clin Oncol 31:1539–1547CrossRef

Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495CrossRefPubMed

Moses AW, Slater C, Preston T et al (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90:996–1002CrossRefPubMedPubMedCentral

Huillard O, Mir O, Peyromaure M et al (2013) Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 108:1034–1041CrossRefPubMedPubMedCentral

Prado CM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res Off J Am Assoc Cancer Res 15:2920–2926CrossRef

Huang DD, Wang SL, Zhuang CL et al (2015) Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer. Colorectal Dis 17:O256–O264CrossRefPubMed

Sharma P, Zargar-Shoshtari K, Caracciolo JT et al (2015) Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol 33:1585–1592CrossRefPubMed

Joglekar S, Nau PN, Mezhir JJ (2015) The impact of sarcopenia on survival and complications in surgical oncology: a review of the current literature. J Surg Oncol 112:503–509CrossRefPubMedPubMedCentral

Ida S, Watanabe M, Yoshida N et al (2015) Sarcopenia is a predictor of postoperative respiratory complications in patients with esophageal cancer. Ann Surg Oncol 22:4432–4437CrossRefPubMed

10.

Smith AB, Deal AM, Yu H et al (2014) Sarcopenia as a predictor of complications and survival following radical cystectomy. J Urol 191:1714–1720CrossRefPubMed

11.

Prado CM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629–635CrossRefPubMed

12.

Sabel MS, Lee J, Cai S et al (2011) Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 18:3579–3585CrossRefPubMed

13.

Harimoto N, Shirabe K, Yamashita YI et al (2013) Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg 100:1523–1530CrossRefPubMed

14.

Prado CM, Wells JC, Smith SR et al (2012) Sarcopenic obesity: a Critical appraisal of the current evidence. Clin Nutr 31:583–601CrossRefPubMed

15.

Psutka SP, Carrasco A, Schmit GD et al (2014) Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer 120:2910–2918CrossRefPubMed

16.

Miyamoto Y, Baba Y, Sakamoto Y et al (2015) Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann Surg Oncol 22:2663–2668CrossRefPubMed

17.

Psutka SP, Boorjian SA, Moynagh MR et al (2016) Decreased skeletal muscle mass is associated with an increased risk of mortality after radical nephrectomy for localized renal cell cancer. J Urol 195:270–276CrossRefPubMed

18.

Sobin L, Wittekind C (2002) International union against cancer (UICC): TNM classification of malignant tumors, 6th edn. Willey-Liss, New York

19.

Sagalowsky A, Jarrett T (2002) Management of urothelial tumors of the renal pelvis and ureter. Campbell’s Urol 4:2845–2875

20.

Antoun S, Lanoy E, Iacovelli R et al (2013) Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer 119:3377–3384CrossRefPubMed

21.

Shen W, Punyanitya M, Wang Z et al (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 97:2333–2338CrossRef

22.

Kondo T, Hara I, Takagi T et al (2014) Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: a prospective study. Int J Urol 21:453–459CrossRefPubMed

23.

Kondo T, Nakazawa H, Ito F et al (2007) Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol 178:1212–1217 (discussion 1217) CrossRefPubMed

24.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213CrossRefPubMedPubMedCentral

25.

Roubenoff R, Hughes VA (2000) Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci 55:M716–M724CrossRefPubMed

26.

Fukushima H, Yokoyama M, Nakanishi Y et al (2015) Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma. PLoS ONE 10:e0115895CrossRefPubMedPubMedCentral

27.

Sharma P, Zargar-Shoshtari K, Caracciolo JT et al (2015) Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urologic oncology 33:339.e317–323

28.

Fukushima H, Nakanishi Y, Kataoka M et al (2016) Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma. J Urol 195:26–32CrossRefPubMed

29.

Taguchi S, Akamatsu N, Nakagawa T et al (2015) Sarcopenia Evaluated Using the Skeletal Muscle Index Is a Significant Prognostic Factor for Metastatic Urothelial Carcinoma. Clinical genitourinary cancer

30.

Grivennikov S, Karin E, Terzic J et al (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103–113CrossRefPubMedPubMedCentral

31.

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867CrossRefPubMedPubMedCentral

32.

Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175–1183CrossRefPubMedPubMedCentral

33.

Margulis V, Shariat SF, Matin SF et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115:1224–1233CrossRefPubMed

34.

Li CC, Chang TH, Wu WJ et al (2008) Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol 54:1127–1134CrossRefPubMed

35.

Bolenz C, Shariat SF, Fernandez MI et al (2009) Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. BJU Int 103:302–306CrossRefPubMed

36.

Waters DL, Baumgartner RN, Garry PJ et al (2010) Advantages of dietary, exercise-related, and therapeutic interventions to prevent and treat sarcopenia in adult patients: an update. Clin Interv Aging 5:259–270CrossRefPubMedPubMedCentral

Titel: Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study
verfasst von: Hiroki Ishihara
Tsunenori Kondo
Kenji Omae
Toshio Takagi
Junpei Iizuka
Hirohito Kobayashi
Yasunobu Hashimoto
Kazunari Tanabe
Publikationsdatum: 15.07.2016
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 1/2017
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-1021-x

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

The role of periodic serum CA19-9 test in surveillance after colorectal cancer surgery

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

Nutritional care of cancer patients: a survey on patients’ needs and medical care in reality

Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer

T-cell lymphomas, a challenging disease: types, treatments, and future

Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie